If food intake drops too low, or food quality becomes poor, that can lead to: Low energy Poor recovery Constipation and digestive issues Loss of lean muscle tissue A greater chance of regaining weight later Medication may help reduce appetite, but it does not remove your body's nutritional needs
Potential considerations include: Theoretical concern about promoting angiogenesis in existing tumors (not demonstrated but mechanistically plausible) Possible interactions with dopaminergic medications Limited human safety data due to absence of completed clinical trials GHK-Cu Side Effects# GHK-Cu has an established safety profile, particularly for topical use: Topical formulations are generally well-tolerated with low irritation potential Allergic reactions are rare but possible, particularly in individuals with copper sensitivity Injection site reactions (redness, swelling) can occur with subcutaneous administration No significant systemic side effects reported at standard research doses The extensive commercial use of GHK-Cu in cosmetic products provides a broader real-world safety dataset compared to BPC-157
Recent clinical trials (Marso et al., 2016, 2017
doi: 10.1016/j.brainres.2014.10.009 167 MarinB.LogroscinoG.BoumdieneF.LabrunieA.CouratierP.BabronM.-C.et al
Additionally, Zepbound (tirzepatide) received approval for obstructive sleep apnea (OSA) in adults with obesity in 2024, marking the first FDA-approved pharmacotherapy for OSA
